naltrexone Articles
Stock Commentary - New York week to April 20, 2009
23 April 2009
Alkermes completes Ph IIIb Vivitrol enrollment
22 April 2009
Stock Commentary - New York week to April 13, 2009
16 April 2009
Stock Commentary - New York week to Feb 16, 2009
23 February 2009
King's Embeda "effective for up to 12 months"
9 February 2009
FDA review of King's Embeda likely to extend into "early 2009"
12 January 2009
Alpharma relents, accepting King Pharma
1 December 2008
Syntropharma raises $2.4M in second round of investment
15 September 2008
Alkermes/J&J's Vivitrol approved in Russia
11 August 2008
Orexigen enrolls Ph III Contrave trial
12 May 2008
Reliant sale boosts Alkermes 3rd-qtr EPS
18 February 2008
Cilag licenses Alkermes
14 January 2008
Strong Ph IIb data on Orexigen's Contrave
29 October 2007
UPDATE: 2007 NASSO conference hears encouraging data on GSK's alli, Orexigen's Contrave et al
29 October 2007
Alkermes sees fiscal 1st-qtr net income of $8.7M
13 August 2007
Alkermes submits Vivitrol MAA in UK and Germany
9 April 2007
Alkermes reports $3M 4th-qtr 2006 net income
19 February 2007
elbion NV acquires candidates from DrugAbuse Sci
5 February 2007
NICE issues guidance on opioid dependence drugs
29 January 2007
OREXIGEN completes $30M financing
27 November 2006
FDA approves Vivitrol for alcohol dependency
24 April 2006
Stock Commentary - New York week to Jan 9
9 January 2006
Vivitrol gains FDA approvable letter
9 January 2006
Cephalon sees 19% sales jump in 2nd qtr
15 August 2005
Stock Commentary - New York
11 July 2005
Cephalon signs Vivitrex deal with Alkermes
4 July 2005
Alkermes' NDA for Vivtrex accepted by the US FDA
6 June 2005
Elite's abuse-resisitant oxycodone gets IND
6 June 2005
Alkermes' Vivitrex shows good performance
18 April 2005
Alkermes: NDA for alcoholism drug
11 April 2005
Alkermes cuts 3rd-qtr loss
14 February 2005
Elite sees promising results for its abuse-resistant technology
17 January 2005
Alkermes reports progress in Vivitrex trial
7 April 2003
Alkermes starts Ph III trial of naltrexone XR
15 April 2002
Fast-track review for Merck/Forest's Campral
11 March 2002
Acamprosate - An Integrative Therapy for Alcoholism
15 July 1996
First Combination Therapy For Bulimia
8 July 1996
New Insights Into Alcohol Abuse
22 April 1996
ReVia Launched In Canada For Alcoholism
29 January 1996
BOC's Revex To Be Launched Soon?
8 May 1995
DuPont Merck's ReVia Gains US Approval For Alcoholism
16 January 1995
ZAMBON LAUNCHES ANTAXONE IN SPAIN
20 April 1992
Showing 1-53 of 53 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
